<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942666</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-06532AA1-03</org_study_id>
    <secondary_id>2019-000250-59</secondary_id>
    <nct_id>NCT03942666</nct_id>
  </id_info>
  <brief_title>PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects</brief_title>
  <official_title>A Clinical Pharmacology Study to Evaluate the CHF 6532 Linearity After Single Oral Administrations of Four Doses of a Tablet Formulation Followed by an Evaluation of the Pharmacokinetic at Steady State Following the Repeated Open Label b.i.d. Administration at One Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical pharmacology study is to evaluate the CHF 6532 linearity after&#xD;
      single oral administrations of four doses of a tablet formulation and to evaluate the&#xD;
      pharmacokinetic (PK) at steady state following the repeated open label b.i.d. administration&#xD;
      at one dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists in two parts. The first study part (Part I) is a single dose, randomised,&#xD;
      double-blind, placebo-controlled, 5-way, 5-period crossover design, in healthy subjects.&#xD;
&#xD;
      The second study part (Part II) is a repeated dose, open label treatment in healthy subjects.&#xD;
&#xD;
      The PK of CHF 6532 and CHF 6532 acyl glucuronide metabolite (CHF 6532-AG), the cardiac safety&#xD;
      will be assessed after single or repeated administration of CHF 6532 tablet formulations in&#xD;
      healthy subjects under fed conditions.&#xD;
&#xD;
      A total of 30 healthy male and female are planned to be included where they will participate&#xD;
      the 2 study parts.&#xD;
&#xD;
      Standard safety assessments will be conducted during the Study, including safety blood and&#xD;
      urine laboratory tests, vital signs, physical examinations, ECGs and observations of any&#xD;
      adverse events. Blood and urines samples will be also collected for PK analysis. Holter&#xD;
      recordings will be performed to build a prospective concentration-response model of QTc for&#xD;
      CHF 6532 in Part I and for cardiac safety purpose at steady state in Part II.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2019</start_date>
  <completion_date type="Actual">November 22, 2019</completion_date>
  <primary_completion_date type="Actual">November 22, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Part I: 5-way, 5-period crossover Part II: single group</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part II: double blind Part II: open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>PK linearity of CHF 6532</measure>
    <time_frame>Over 12 hours after administration in urine, over 48 hours after administration in blood</time_frame>
    <description>Assessment of CHF 6532 PK linearity in blood and urine depending on increasing doses of CHF 6532</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady state PK of CHF 6532</measure>
    <time_frame>Over 12 hours after administration at Day 1 and Day 10 in urine, over 12 hours after administration at Day 1 and over 24 hours after administration at Day 10 in blood</time_frame>
    <description>Assessment of CHF 6532 PK in blood and urine after a repeated administration of CHF 6532</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac Safety of CHF 6532</measure>
    <time_frame>Over 24 hours after single administration in Part I, Over 24 hours at Day 10 in Part II</time_frame>
    <description>Holter recording</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK linearity of CHF 6532-AG</measure>
    <time_frame>Over 12 hours after administration in urine, over 48 hours after administration in blood</time_frame>
    <description>Assessment of CHF 6532-AG PK in blood and urine depending on increasing doses of CHF 6532</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state PK of CHF 6532-AG</measure>
    <time_frame>Over 12 hours after administration at Day 1 and Day 10 in urine, over 12 hours after administration at Day 1 and over 24 hours after administration at Day 10 in blood</time_frame>
    <description>Assessment of CHF 6532-AG PK in blood and urine after a repeated administration of CHF 6532</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of CHF 6532 Dose #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of CHF 6532 Dose #2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of CHF 6532 Dose #3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of CHF 6532 Dose #4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single administration of CHF 6532 Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment F</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Part II: Administration of tablet of CHF 6532 b.i.d. for 10 days at one dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A</intervention_name>
    <description>tablet of CHF 6532</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B</intervention_name>
    <description>tablet of CHF 6532</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C</intervention_name>
    <description>tablet of CHF 6532</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment D</intervention_name>
    <description>tablet of CHF 6532</description>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment E</intervention_name>
    <description>Placebo tablet of CHF 6532</description>
    <arm_group_label>Treatment E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment F</intervention_name>
    <description>tablet of CHF 6532</description>
    <arm_group_label>Treatment F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject's written informed consent obtained prior to any study-related procedure;&#xD;
&#xD;
          -  Healthy male or female subjects aged 18-60 years inclusive;&#xD;
&#xD;
          -  Ability to understand the study procedures, the risks involved and willingness to&#xD;
             follow the study procedures including intake of non-permitted concomitant medications;&#xD;
&#xD;
          -  Body Mass Index (BMI) between 19.0 and 30.0 kg/m2 extremes inclusive;&#xD;
&#xD;
          -  Non- or ex-smokers who smoked &lt; 5 pack years;&#xD;
&#xD;
          -  Good physical and mental status, determined on the basis of the medical history and a&#xD;
             general physical examination;&#xD;
&#xD;
          -  Vital signs within normal limits;&#xD;
&#xD;
          -  Body temperature 35.5-37.2ÂºC;&#xD;
&#xD;
          -  12-lead digitised Electrocardiogram (12-lead ECG) considered as normal;&#xD;
&#xD;
          -  Female subject of non-childbearing potential (WONCBP) defined as physiologically&#xD;
             incapable of becoming pregnant (i.e. post-menopausal or permanently sterile) and&#xD;
             female subjects of childbearing potential (WOCBP) fulfilling one of the following&#xD;
             criteria: a/ WOCBP with fertile male partners: they and/or their partner must be&#xD;
             willing to use a highly effective birth control method from the signature of the&#xD;
             informed consent and until the follow-up visit or b/WOCBP with non-fertile male&#xD;
             partners: (contraception is not required in this case).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant abnormal 24 hours Holter ECG at screening;&#xD;
&#xD;
          -  Subjects with history of sustained and non-sustained cardiac arrhythmias (ECG&#xD;
             demonstrated) and subjects with a family history of sudden cardiac death;&#xD;
&#xD;
          -  Blood donation or blood loss (equal or more than 450 ml) less than 8 weeks prior to&#xD;
             randomisation;&#xD;
&#xD;
          -  Abnormal haemoglobin level;&#xD;
&#xD;
          -  Subjects with history of asthma, including childhood asthma, COPD or any other chronic&#xD;
             pulmonary diseases or condition;&#xD;
&#xD;
          -  Positive HIV1 or HIV2 serology;&#xD;
&#xD;
          -  Positive results for the Hepatitis serology;&#xD;
&#xD;
          -  Clinically relevant and uncontrolled hepatic, gastrointestinal, endocrine, metabolic&#xD;
             (specially, subjects with deficiency in glucuronidation), neurologic, or psychiatric&#xD;
             disorder that may interfere with successful completion of this protocol according to&#xD;
             the Investigator's judgement;&#xD;
&#xD;
          -  Any clinically relevant abnormal laboratory value suggesting an unknown disease and&#xD;
             requiring further clinical investigation or which may impact the safety of the subject&#xD;
             or the evaluation of the result of the study according to the Investigator's judgment;&#xD;
&#xD;
          -  Abnormal liver enzymes;&#xD;
&#xD;
          -  Unsuitable veins for repeated venepuncture;&#xD;
&#xD;
          -  History of substance abuse or drug abuse within 12 months prior to screening;&#xD;
&#xD;
          -  Subjects who have received an investigational drug or device within 1 month or 7 times&#xD;
             the elimination half-life (whichever is longer) prior to screening visit or are&#xD;
             currently participating in another clinical trial or have been previously randomised&#xD;
             in this trial;&#xD;
&#xD;
          -  History of hypersensitivity to any of the excipients contained in the formulation used&#xD;
             in the trial;&#xD;
&#xD;
          -  Known intolerance/hypersensitivity to quinolone-type antibiotics, e.g. moxifloxacin,&#xD;
             norfloxacin, ciprofloxacin, nalidixic acid;&#xD;
&#xD;
          -  Heavy caffeine drinker;&#xD;
&#xD;
          -  Subjects who have a positive urine test;&#xD;
&#xD;
          -  Subject taking any drug treatment, including prescribed or OTC medicines as well as&#xD;
             vitamins, homeopathic remedies etc, in the 14 days before the screening until&#xD;
             randomisation, with the exception of: Occasional paracetamol, Hormonal contraceptives,&#xD;
             Hormonal replacement treatment for post-menopausal women;&#xD;
&#xD;
          -  Subject taking enzyme-inducing drugs, enzyme-inhibiting drugs, biologic drugs or any&#xD;
             drug known to have a well-defined potential for hepatotoxicity (e.g. isoniazide,&#xD;
             nimesulide, ketoconazole) in the 3 months before screening until randomisation;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  History of risk factors for torsades de pointes, including unexplained syncope, known&#xD;
             long QT syndrome, heart failure, myocardial infarction, angina or symptomatic&#xD;
             arrhythmias. Subjects will also be excluded if there is a family history of long QT&#xD;
             syndrome or Brugada syndrome or unexplained sudden death;&#xD;
&#xD;
          -  Use of medications which are known to carry a risk of prolong the QTc interval is not&#xD;
             allowed within 14 days or 7 times the elimination half-life (whichever is longer)&#xD;
             before the baseline ECG.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SGS Life Sciences - Clinical Pharmacology Unit Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

